- EndoCellutions has raised $20k from founders, and $500k of at risk financing through a Series A equity offering in Q3 2010. EndoCellutions has also secured $80k in federal grants. This funding has been used to develop and optimize technologies for preparing bone marrow aspirate concentration as well as platelet-rich plasma preparation devices, and should be sufficient to complete FDA regulatory work on these devices (estimated Q3 2012).